- Target amount for life sciences fund is unclear
- Themes: inflection capital, growth capital, fallen angels, larger PE
- Team: Adam Koppel, Jeffrey Schwartz, Ricky Sun
Bain Capital is raising money for Bain Capital Life Sciences Fund LP, a regulatory filing shows. The document does not say how much the fund is targeting.
According to a website created for the business, baincapitallifesciences.com, “several long-term trends in healthcare … are creating an increased need for targeted capital and value-added strategic support of companies around their critical phases of growth,” prompting the launch of a dedicated life sciences fund.
Bain has heretofore invested in the industry through business units including private equity, public equity, credit, and ventures.
The site also says the new division will pursue a “[f]ocused strategy across four themes of investments”: inflection capital, growth capital, fallen angels and larger private equity. Targets include biopharmaceutical, specialty pharmaceutical, medical device, diagnostics and enabling life sciences technology companies.
Bain’s life sciences team consists of Managing Directors Adam Koppel and Jeffrey Schwartz and Principal Ricky Sun. Koppel and Sun have Ph.D.s, in neuroscience and chemistry, respectively. Koppel is also a physician.
Bain has recently rebranded certain business units. In April, the firm gave the Bain name to both its credit affiliate, Sankaty Advisors, and its public-equity unit, Brookside Capital, The Wall Street Journal reported.
Clarification: This report has been updated to clarify the circumstances of Bain’s recent business unit rebrandings.
Image of DNA strands courtesy ©iStock/ilexx